iKaryos Diagnostics Offers Cancer Diagnostic Services to Asia Pacific and Middle East

PALO ALTO, Calif.--(BUSINESS WIRE)--iKaryos Diagnostics Inc. today announced an exclusive distribution agreement extending its cancer diagnostic services to Australia, Egypt, Hong Kong, Korea, Kuwait, Saudi Arabia, Singapore, and United Arab Emirates through regional distributors.

“Using SNP array karyotyping, we can obtain karyotypes on tumors that have been paraffin embedded. We can now see genomic changes too small to be detected by conventional karyotyping and ones that are useful for personalized medicine, diagnosis and prognosis”

iKaryos is the first and only company to market SNP array Virtual Karyotype cancer diagnostic services, which provide genome-wide copy number and loss-of-heterozygosity (LOH) information at an unprecedented resolution. SNP array Virtual Karyotypes are the only clinically available methodology that can readily detect copy neutral LOH, a newly appreciated common genetic lesion in human tumors.

“Using SNP array karyotyping, we can obtain karyotypes on tumors that have been paraffin embedded. We can now see genomic changes too small to be detected by conventional karyotyping and ones that are useful for personalized medicine, diagnosis and prognosis,” said Fahd Al-Mulla, M.D., Ph.D., associate professor and head, Molecular Pathology, Kuwait University. “Like many laboratories, we do not have the in-house expertise necessary to analyze this type of data ourselves, but through iKaryos, we can still provide this valuable information to our oncologists and pathologists.”

“The response to our SNP array Virtual Karyotype cancer diagnostic test has been tremendous. We are very excited to now offer our services in the Middle East and Asia, two of the fastest growing molecular diagnostic markets with high per capita spending and an increasing cancer burden,” said Robert Klein, Ph.D., founder and CEO, iKaryos Diagnostics. “We have already received interest from physicians in these regions and now we will be able to distribute to these markets much more effectively.”

All diagnostic reports from iKaryos are prepared by board-certified molecular pathologists with extensive training and experience in the validation and interpretation of complex molecular assays. iKaryos has an extensive database of previously analyzed samples against which new results can be compared. The SNP array Virtual Karyotype assay is clinically validated for both fresh and formalin fixed, paraffin-embedded tumors. To order a test or to get more information, please visit: http://www.ikaryos.com/order-a-test.html.

About iKaryos Diagnostics

iKaryos Diagnostics provides better diagnostic, prognostic and therapeutic information for cancer patients and their physicians. iKaryos Diagnostics is a privately held company headquartered in Palo Alto, Calif., with a CLIA- and CAP-certified diagnostic laboratory operated in collaboration with Creighton University in Omaha, Neb. For more information, please visit www.iKaryos.com.